Evaluation of plasma and urinary levels of 6-keto-prostaglandin F1a as a marker for asymptomatic myxomatous mitral valve disease in dogs

Caroline Elisabeth Rasmussen; Anna Vilhelmina Sundqvist; Christina Tirsdal Kjempff; Inge Tarnow; Mads Kjelgaard-Hansen; Thea Sigbrit Kamstrup; Annelise Sterup; Tina Møller Sørensen; Lisbeth Høier Olsen

doi:10.1016/j.tvjl.2009.02.012

Evaluation of plasma and urinary levels of 6-keto-prostaglandin F_1a as a marker for asymptomatic myxomatous mitral valve disease in dogs

Caroline Elisabeth Rasmussen, Anna Vilhelmina Sundqvist, Christina Tirsdal Kjempff, Inge Tarnow, Mads Kjelgaard-Hansen, Thea Sigbrit Kamstrup, Annelise Sterup, Tina Møller Sørensen, Lisbeth Høier Olsen

2 Citationer (Scopus)

Abstract

Endothelial dysfunction might be involved in the pathogenesis of myxomatous mitral valve disease (MMVD). The aims of this study were (1) to validate an enzyme immunoassay (EIA) for canine 6-keto-prostaglandin (PG)F_1α (prostacyclin metabolite and marker for endothelial function) and (2) to compare plasma and urinary 6-keto-PGF_1α in dogs with asymptomatic MMVD. The study included two breeds predisposed to MMVD and two control groups (Cairn terriers and dogs of different breeds). Echocardiography was used to estimate the severity of MMVD. The intra- and inter-assay coefficients of variation were between 3.1% and 24.5% in the assay range. No echocardiographic parameter was correlated with plasma or urinary 6-keto-PGF_1α (P > 0.05), but all control dogs had lower urinary 6-keto-PGF_1α (P < 0.02) and the Cairn terriers had higher plasma 6-keto-PGF_1α (P < 0.02). The EIA appeared valid for measuring canine 6-keto-PGF_1α in plasma and urine. It is suggested that 6-keto-PGF_1α levels are related to breed and not MMVD in asymptomatic stages.

Originalsprog	Engelsk
Tidsskrift	Veterinary Journal
Vol/bind	184
Udgave nummer	2
Sider (fra-til)	241-246
Antal sider	6
ISSN	1090-0233
DOI	https://doi.org/10.1016/j.tvjl.2009.02.012
Status	Udgivet - maj 2010

Adgang til dokumentet

10.1016/j.tvjl.2009.02.012

Citationsformater

Rasmussen, C. E., Sundqvist, A. V., Kjempff, C. T., Tarnow, I., Kjelgaard-Hansen, M., Kamstrup, T. S., Sterup, A., Sørensen, T. M., & Olsen, L. H. (2010). Evaluation of plasma and urinary levels of 6-keto-prostaglandin F_1a as a marker for asymptomatic myxomatous mitral valve disease in dogs. Veterinary Journal, 184(2), 241-246. https://doi.org/10.1016/j.tvjl.2009.02.012

Evaluation of plasma and urinary levels of 6-keto-prostaglandin F_1a as a marker for asymptomatic myxomatous mitral valve disease in dogs. / Rasmussen, Caroline Elisabeth ; Sundqvist, Anna Vilhelmina; Kjempff, Christina Tirsdal et al.
I: Veterinary Journal, Bind 184, Nr. 2, 05.2010, s. 241-246.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

@article{4cc7d260ea2f11deba73000ea68e967b,

title = "Evaluation of plasma and urinary levels of 6-keto-prostaglandin F1a as a marker for asymptomatic myxomatous mitral valve disease in dogs",

abstract = "Endothelial dysfunction might be involved in the pathogenesis of myxomatous mitral valve disease (MMVD). The aims of this study were (1) to validate an enzyme immunoassay (EIA) for canine 6-keto-prostaglandin (PG)F1α (prostacyclin metabolite and marker for endothelial function) and (2) to compare plasma and urinary 6-keto-PGF1α in dogs with asymptomatic MMVD. The study included two breeds predisposed to MMVD and two control groups (Cairn terriers and dogs of different breeds). Echocardiography was used to estimate the severity of MMVD. The intra- and inter-assay coefficients of variation were between 3.1% and 24.5% in the assay range. No echocardiographic parameter was correlated with plasma or urinary 6-keto-PGF1α (P > 0.05), but all control dogs had lower urinary 6-keto-PGF1α (P < 0.02) and the Cairn terriers had higher plasma 6-keto-PGF1α (P < 0.02). The EIA appeared valid for measuring canine 6-keto-PGF1α in plasma and urine. It is suggested that 6-keto-PGF1α levels are related to breed and not MMVD in asymptomatic stages.",

author = "Rasmussen, {Caroline Elisabeth} and Sundqvist, {Anna Vilhelmina} and Kjempff, {Christina Tirsdal} and Inge Tarnow and Mads Kjelgaard-Hansen and Kamstrup, {Thea Sigbrit} and Annelise Sterup and S{\o}rensen, {Tina M{\o}ller} and Olsen, {Lisbeth H{\o}ier}",

year = "2010",

month = may,

doi = "10.1016/j.tvjl.2009.02.012",

language = "English",

volume = "184",

pages = "241--246",

journal = "Veterinary Journal",

issn = "1090-0233",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Evaluation of plasma and urinary levels of 6-keto-prostaglandin F1a as a marker for asymptomatic myxomatous mitral valve disease in dogs

AU - Rasmussen, Caroline Elisabeth

AU - Sundqvist, Anna Vilhelmina

AU - Kjempff, Christina Tirsdal

AU - Tarnow, Inge

AU - Kjelgaard-Hansen, Mads

AU - Kamstrup, Thea Sigbrit

AU - Sterup, Annelise

AU - Sørensen, Tina Møller

AU - Olsen, Lisbeth Høier

PY - 2010/5

Y1 - 2010/5

N2 - Endothelial dysfunction might be involved in the pathogenesis of myxomatous mitral valve disease (MMVD). The aims of this study were (1) to validate an enzyme immunoassay (EIA) for canine 6-keto-prostaglandin (PG)F1α (prostacyclin metabolite and marker for endothelial function) and (2) to compare plasma and urinary 6-keto-PGF1α in dogs with asymptomatic MMVD. The study included two breeds predisposed to MMVD and two control groups (Cairn terriers and dogs of different breeds). Echocardiography was used to estimate the severity of MMVD. The intra- and inter-assay coefficients of variation were between 3.1% and 24.5% in the assay range. No echocardiographic parameter was correlated with plasma or urinary 6-keto-PGF1α (P > 0.05), but all control dogs had lower urinary 6-keto-PGF1α (P < 0.02) and the Cairn terriers had higher plasma 6-keto-PGF1α (P < 0.02). The EIA appeared valid for measuring canine 6-keto-PGF1α in plasma and urine. It is suggested that 6-keto-PGF1α levels are related to breed and not MMVD in asymptomatic stages.

AB - Endothelial dysfunction might be involved in the pathogenesis of myxomatous mitral valve disease (MMVD). The aims of this study were (1) to validate an enzyme immunoassay (EIA) for canine 6-keto-prostaglandin (PG)F1α (prostacyclin metabolite and marker for endothelial function) and (2) to compare plasma and urinary 6-keto-PGF1α in dogs with asymptomatic MMVD. The study included two breeds predisposed to MMVD and two control groups (Cairn terriers and dogs of different breeds). Echocardiography was used to estimate the severity of MMVD. The intra- and inter-assay coefficients of variation were between 3.1% and 24.5% in the assay range. No echocardiographic parameter was correlated with plasma or urinary 6-keto-PGF1α (P > 0.05), but all control dogs had lower urinary 6-keto-PGF1α (P < 0.02) and the Cairn terriers had higher plasma 6-keto-PGF1α (P < 0.02). The EIA appeared valid for measuring canine 6-keto-PGF1α in plasma and urine. It is suggested that 6-keto-PGF1α levels are related to breed and not MMVD in asymptomatic stages.

U2 - 10.1016/j.tvjl.2009.02.012

DO - 10.1016/j.tvjl.2009.02.012

M3 - Journal article

C2 - 19324577

SN - 1090-0233

VL - 184

SP - 241

EP - 246

JO - Veterinary Journal

JF - Veterinary Journal

IS - 2

ER -